Connect with us

Technology

ASE Technology Holding Co., Ltd. Reports Its Unaudited Consolidated Financial Results for the Third Quarter of 2024

Published

on

TAIPEI, Oct. 31, 2024 /PRNewswire/ — ASE Technology Holding Co., Ltd. (TWSE: 3711, NYSE: ASX) (“We”, “ASEH”, or the “Company”), the leading provider of semiconductor assembly and testing services (“ATM”) and the provider of electronic manufacturing services (“EMS”), today reported its unaudited net revenues[1] of NT$160,105 million for 3Q24, up by 3.9% year-over-year and up by 14.2% sequentially. Net income attributable to shareholders of the parent for the quarter totaled NT9,666 million, up from NT$8,776 million in 3Q23 and up from NT$7,778 million in 2Q24.  Basic earnings per share for the quarter were NT$2.24 (or US$0.138 per ADS), compared to NT$2.04 for 3Q23 and NT$1.80 for 2Q24. Diluted earnings per share for the quarter were NT$2.17 (or US$0.134 per ADS), compared to NT$2.00 for 3Q23 and NT$1.75 for 2Q24.

As of September 30, 2024, we have completed the PPA and have retrospectively adjusted the consolidated financial results for prior period.

RESULTS OF OPERATIONS

3Q24 Results Highlights – Consolidated

Net revenues from packaging operations, testing operations, EMS operations, and others represented approximately 43%, 9%, 47%, and 1% of the total net revenues for the quarter, respectively.Cost of revenues was NT$133,673 million for the quarter, up from NT$117,184 million in 2Q24.Raw material cost totaled NT$84,658 million for the quarter, representing 53% of the total net revenues.Labor cost totaled NT$16,468 million for the quarter, representing 10% of the total net revenues.Depreciation, amortization and rental expenses totaled NT$13,647 million for the quarter.Gross margin increased by 0.1 percentage points to 16.5% in 3Q24 from 16.4% in 2Q24.Operating margin was 7.2% in 3Q24, compared to 6.4% in 2Q24.In terms of non-operating items:Net interest expense was NT$1,291 million.Net foreign exchange gain was NT$1,890 million, primarily attributable to the depreciation of the U.S. dollar against the New Taiwan dollar.Net loss on valuation of financial assets and liabilities was NT$943 million.Net gain on equity-method investments was NT$485 million.Other net non-operating income was NT$643 million, primarily attributable to miscellaneous income.
Total non-operating income and expenses for the quarter was NT$784 million.Income before tax was NT$12,260 million in 3Q24, compared to NT$10,105 million in 2Q24. We recorded income tax expenses of NT$2,054 million for the quarter, compared to NT$1,950 million in 2Q24.Net income attributable to shareholders of the parent was NT$9,666 million in 3Q24, compared to NT$8,776 million in 3Q23 and NT$7,778 million in 2Q24.Our total number of shares outstanding at the end of the quarter was 4,412,064,337, including treasury stock owned by our subsidiaries in 3Q24. Our 3Q24 basic earnings per share of NT$2.24 (or US$0.138 per ADS) were based on 4,321,735,473 weighted average numbers of shares outstanding in 3Q24. Our 3Q24 diluted earnings per share of NT$2.17 (or US$0.134 per ADS) were based on 4,391,466,234 weighted average number of shares outstanding in 3Q24.

3Q24 Results Highlights – ATM

Net revenues were NT$85,790 million for the quarter, up by 2.5% year-over-year and up by 10.3% sequentially.Cost of revenues was NT$65,989 million for the quarter, up by 1.4% year-over-year and up by 8.9% sequentially.Raw material cost totaled NT$24,177 million for the quarter, representing 28% of the total net revenues.Labor cost totaled NT$13,309 million for the quarter, representing 16% of the total net revenues.Depreciation, amortization and rental expenses totaled NT$12,163 million for the quarter.Gross margin increased by 1.0 percentage points to 23.1% in 3Q24 from 22.1% in 2Q24.Operating margin was 10.8% in 3Q24, compared to 9.3% in 2Q24.

3Q24 Results Highlights – EMS

Net revenues were NT$75,384 million, up by 6.2% year-over-year and up by 19.8% sequentially.Cost of revenues for the quarter was NT$68,627 million, up by 6.4% year-over-year and up by 20.6% sequentially.Raw material cost totaled NT$60,912 million for the quarter, representing 81% of the total net revenues.Labor cost totaled NT$3,051 million for the quarter, representing 4% of the total net revenues.Depreciation, amortization and rental expenses totaled NT$1,219 million for the quarter.Gross margin decreased by 0.6 percentage points to 9.0% in 3Q24 from 9.6% in 2Q24.Operating margin was 3.3% in 3Q24, compared to 3.1% in 2Q24.

LIQUIDITY AND CAPITAL RESOURCES

Capital expenditures in 3Q24 totaled US$603 million, of which US$312 million was used in packaging operations, US$274 million in testing operations, US$14 million in EMS operations and US$3 million in interconnect materials operations and others.Total unused credit lines amounted to NT$361,264 million as of September 30, 2024.Current ratio was 1.18 and net debt to equity ratio was 0.41 as of September 30, 2024.Total number of employees was 94,456 as of September 30, 2024, compared to 92,243 as of June 30, 2024.

BUSINESS REVIEW

Customers
ATM BASIS

Our five largest customers together accounted for approximately 46% of our total net revenues in 3Q24, compared to 45% in 2Q24. One customer accounted for more than 10% of our total net revenues in 3Q24.Our top 10 customers contributed 61% of our total net revenues in 3Q24, compared to 60% in 2Q24.Our customers that are integrated device manufacturers or IDMs accounted for 31% of our total net revenues in 3Q24, compared to 30% in 2Q24.

EMS BASIS

Our five largest customers together accounted for approximately 72% of our total net revenues in 3Q24, compared to 67% in 2Q24. One customer accounted for more than 10% of our total net revenues in 3Q24.Our top 10 customers contributed 78% of our total net revenues in 3Q24, compared to 74% in 2Q24.

About ASE Technology Holding Co., Ltd.
ASEH is the leading provider of semiconductor manufacturing services in assembly and test. The Company develops and offers complete turnkey solutions covering front-end engineering test, wafer probing and final test, as well as packaging, materials and electronic manufacturing services through USI with superior technologies, breakthrough innovations, and advanced development programs. With advanced technological capabilities and a global presence spanning Taiwan, China, South Korea, Japan, Singapore, Malaysia, Philippines, Vietnam, Mexico, and Tunisia as well as the United States and Europe, ASEH has established a reputation for reliable, high quality products and services.

For more information, please visit our website at https://www.aseglobal.com.

Safe Harbor Notice
This press release contains “forward-looking statements” within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although these forward-looking statements, which may include statements regarding our future results of operations, financial condition or business prospects, are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan” and similar expressions, as they relate to us, are intended to identify these forward-looking statements in this press release. These forward-looking statements are necessarily estimates reflecting the best judgment of our senior management and our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied by the forward-looking statements for reasons including, among others, risks associated with cyclicality and market conditions in the semiconductor or electronic industry; changes in our regulatory environment, including our ability to comply with new or stricter environmental regulations and to resolve environmental liabilities; demand for the outsourced semiconductor packaging, testing and electronic manufacturing services we offer and for such outsourced services generally; the highly competitive semiconductor or manufacturing industry we are involved in; our ability to introduce new technologies in order to remain competitive; international business activities; our business strategy; our future expansion plans and capital expenditures; the strained relationship between the Republic of China and the People’s Republic of China; general economic and political conditions; the recent shift in United States trade policies; possible disruptions in commercial activities caused by natural or human-induced disasters; fluctuations in foreign currency exchange rates; and other factors. For a discussion of these risks and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including the 2023 Annual Report on Form 20-F filed on April 3, 2024.

Supplemental Financial Information
(Unaudited)

Consolidated Operations

3Q24

2Q24

3Q23

EBITDA[2] (NT$ million)

28,621

26,127

27,822

ATM Operations

3Q24

2Q24

3Q23

Net Revenues (NT$ million)

85,790

77,813

83,684

Revenues by Application

Communication

50 %

49 %

52 %

Computing

18 %

19 %

19 %

Automotive, Consumer & Others

32 %

32 %

29 %

Revenues by Type

Bumping, Flip Chip, WLP & SiP

45 %

44 %

44 %

Wirebonding

29 %

31 %

32 %

Others

8 %

7 %

8 %

Testing

16 %

16 %

15 %

Material

2 %

2 %

1 %

Capacity & EBITDA

CapEx[3] (US$ million)

588

374

210

EBITDA[2] (NT$ million)

24,186

22,205

23,117

Number of Wirebonders

25,373

25,154

26,215

Number of Testers

5,966

5,676

5,510

EMS Operations

3Q24

2Q24

3Q23

Net Revenues (NT$ million)

75,384

62,907

70,970

Revenues by Application

Communication

34 %

33 %

34 %

Computing

9 %

11 %

8 %

Consumer

36 %

29 %

37 %

Industrial

11 %

13 %

12 %

Automotive

9 %

11 %

7 %

Others

1 %

3 %

2 %

Capacity 

CapEx[3] (US$ million)

14

31

28

ASE Technology Holding Co., Ltd.
Summary of Consolidated Statement of Income Data
(In NT$ million, except per share data)
(Unaudited)

For the three months ended

For the nine months ended

Sep. 30

2024

Jun. 30 2024

(Retrospectively Adjusted)

Sep. 30

2023

Sep. 30

2024

Sep. 30

2023

Net revenues

Packaging

69,154

62,834

68,709

191,447

190,584

Testing

14,124

12,623

12,819

38,848

36,518

EMS

74,871

62,853

70,948

197,050

189,063

Others

1,956

1,928

1,691

5,801

5,168

Total net revenues

160,105

140,238

154,167

433,146

421,333

Cost of revenues

(133,673)

(117,184)

(129,251)

(362,839)

(355,337)

Gross profit

26,432

23,054

24,916

70,307

65,996

Operating expenses

Research and development

(7,439)

(7,106)

(6,759)

(21,154)

(18,549)

Selling, general and administrative

(7,517)

(6,939)

(6,752)

(21,191)

(18,934)

Total operating expenses

(14,956)

(14,045)

(13,511)

(42,345)

(37,483)

Operating income

11,476

9,009

11,405

27,962

28,513

Net non-operating income and expenses

Interest expense – net

(1,291)

(1,158)

(1,247)

(3,557)

(3,424)

Foreign exchange gain (loss) – net

1,890

(1,420)

(2,090)

(2,748)

(2,733)

Gain (Loss) on valuation of financial assets and liabilities – net

(943)

2,664

2,820

5,819

4,837

Gain on equity-method investments – net

485

459

656

1,001

970

Others – net

643

551

708

1,700

2,070

Total non-operating income and expenses

784

1,096

847

2,215

1,720

Income before tax

12,260

10,105

12,252

30,177

30,233

Income tax expense

(2,054)

(1,950)

(2,890)

(5,897)

(6,582)

Income from operations and before non-controlling interests

10,206

8,155

9,362

24,280

23,651

Non-controlling interests

(540)

(377)

(586)

(1,176)

(1,318)

Net income attributable to shareholders of the parent

9,666

7,778

8,776

23,104

22,333

Per share data:

Earnings per share

– Basic

NT$2.24

NT$1.80

NT$2.04

NT$5.35

NT$5.20

– Diluted

NT$2.17

NT$1.75

NT$2.00

NT$5.17

NT$5.05

Earnings per equivalent ADS

– Basic

US$0.138

US$0.112

US$0.130

US$0.335

US$0.338

– Diluted

US$0.134

US$0.109

US$0.127

US$0.324

US$0.328

Number of weighted average shares used in diluted EPS calculation ( in thousand shares)

4,391,465

4,383,325

4,347,752

4,385,913

4,346,129

FX (NTD/USD)

32.31

32.23

31.45

31.95

30.81

ASE Technology Holding Co., Ltd.
Summary of ATM Statement of Income Data
(In NT$ million) 
(Unaudited)

For the three months ended

For the nine months ended

Sep. 30

2024

Jun. 30

 2024

Sep. 30

2023

Sep. 30

2024

Sep. 30

2023

Net revenues:

Packaging

70,290

63,838

69,731

194,516

193,108

Testing

14,124

12,623

12,819

38,848

36,518

Direct Material

1,295

1,264

1,098

3,898

3,369

Others

81

88

36

250

116

Total net revenues

85,790

77,813

83,684

237,512

233,111

Cost of revenues

(65,989)

(60,612)

(65,094)

(184,952)

(183,611)

Gross profit

19,801

17,201

18,590

52,560

49,500

Operating expenses:

Research and development

(5,773)

(5,483)

(5,344)

(16,392)

(14,361)

Selling, general and administrative

(4,803)

(4,464)

(4,426)

(13,612)

(12,505)

Total operating expenses

(10,576)

(9,947)

(9,770)

(30,004)

(26,866)

Operating income

9,225

7,254

8,820

22,556

22,634

ASE Technology Holding Co., Ltd.
Summary of EMS Statement of Income Data
(In NT$ million) 
(Unaudited)

For the three months ended

For the nine months ended

Sep. 30

2024

Jun. 30 2024

(Retrospectively Adjusted)

Sep. 30

2023

Sep. 30

2024

Sep. 30

2023

Net revenues

Total net revenues

75,384

62,907

70,970

197,656

189,127

Cost of revenues

(68,627)

(56,882)

(64,500)

(179,422)

(172,451)

Gross profit

6,757

6,025

6,470

18,234

16,676

Operating expenses

Research and development

(1,668)

(1,668)

(1,453)

(4,869)

(4,304)

Selling, general and administrative

(2,636)

(2,415)

(2,250)

(7,360)

(6,191)

Total operating expenses

(4,304)

(4,083)

(3,703)

(12,229)

(10,495)

Operating income

2,453

1,942

2,767

6,005

6,181

ASE Technology Holding Co., Ltd.
Summary of Consolidated Balance Sheet Data
(In NT$ million)
(Unaudited)

As of Sep. 30, 2024

As of Jun. 30, 2024

(Retrospectively Adjusted)

Current assets

Cash and cash equivalents

71,711

66,173

Financial assets – current

6,643

9,162

Trade receivables

114,061

102,361

Inventories

68,986

63,495

Others

17,364

29,144

Total current assets

278,765

270,335

Financial assets – non-current & Investments – equity -method

42,300

30,887

Property, plant and equipment

283,447

271,870

Right-of-use assets

11,499

11,292

Intangible assets

68,038

68,316

Others

30,510

30,291

Total assets

714,559

682,991

Current liabilities

Short-term borrowings[4]

56,726

51,065

Current portion of bonds payable & Current portion of  long-term borrowings

23,531

18,655

Trade payables

82,595

70,906

Others

72,830

89,495

Total current liabilities

235,682

230,121

Bonds payable

17,073

21,976

Long-term borrowings

108,003

84,414

Other liabilities

22,748

23,053

Total liabilities

383,506

359,564

Equity attributable to shareholders of the parent

309,399

302,323

Non-controlling interests

21,654

21,104

Total liabilities & shareholders’ equity

714,559

682,991

Current ratio

1.18

1.17

Net debt to equity ratio

0.41

0.34

ASE Technology Holding Co., Ltd.
Summary of Consolidated Statement of Cash Flow Data
(In NT$ million)
(Unaudited)

        For the three months ended

For the nine months ended

Sep. 30

2024

Jun. 30 2024

(Retrospectively Adjusted)

Sep. 30

2023

Sep. 30

2024

Sep. 30

2023

Cash Flows from Operating Activities

Profit before income tax

12,260

10,105

12,252

30,177

30,233

Depreciation & amortization

15,037

14,813

14,568

44,449

43,495

Other operating activities items

(5,235)

(8,132)

(5,940)

(19,083)

(6,134)

Net cash generated from operating activities

22,062

16,786

20,880

55,543

67,594

Cash Flows from Investing Activities

Net payments for property, plant

and equipment

(19,769)

(14,786)

(14,471)

(47,068)

(41,824)

Other investment activities items

(2,593)

304

(151)

(5,284)

(2,021)

Net cash used in investing activities

(22,362)

(14,482)

(14,622)

(52,352)

(43,845)

Cash Flows from Financing Activities

Total net proceeds from (repayment of) borrowings and bonds

30,909

(12,330)

28,640

18,439

13,624

Dividends paid

(22,460)

(37,841)

(22,460)

(37,841)

Other financing activities items

(51)

(1,093)

(38)

(1,177)

(977)

Net cash generated from (used in) financing activities

8,398

(13,423)

(9,239)

(5,198)

(25,194)

Foreign currency exchange effect

(2,560)

2,187

6,443

6,434

6,478

Net increase (decrease) in cash

and cash equivalents

5,538

(8,932)

3,462

4,427

5,033

Cash and cash equivalents at the beginning of period

66,173

75,105

59,351

67,284

58,040

Cash and cash equivalents at the

end of period

71,711

66,173

62,813

71,711

63,073

Cash and cash equivalents in the consolidated balance sheet

71,711

66,173

62,812

71,711

62,812

Cash and cash equivalents included in disposal groups held for sale

1

261

 

[1] All financial information presented in this press release is unaudited, consolidated and prepared in accordance with Taiwan-IFRS (International Financial Reporting Standards as endorsed for use in the R.O.C.).  Such financial information is generated internally by us and has not been subjected to the same review and scrutiny, including internal auditing procedures and audit by our independent auditors, to which we subject our year-end audited consolidated financial statements, and may vary materially from the year-end audited consolidated financial information for the same period.  Any evaluation of the financial information presented in this press release should also take into account our published year-end audited consolidated financial statements and the notes to those statements.  In addition, the financial information presented is not necessarily indicative of our results of operations for any future period.

[2] EBITDA stands for net income or loss before interest, taxes, depreciation, amortization, impairment and investment gain or loss as well as other items.

[3] Capital expenditure excludes building construction costs.

[4] Short-term borrowings include short-term loans and bills payable.

 

Investor Relations Contact
ir@aseglobal.com
Tel: +886.2.6636.5678
https://www.aseglobal.com

View original content:https://www.prnewswire.com/news-releases/ase-technology-holding-co-ltd-reports-its-unaudited-consolidated-financial-results-for-the-third-quarter-of-2024-302292377.html

SOURCE ASE Technology Holding Co., Ltd.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Weibo Corporation to Report First Quarter 2026 Financial Results on May 28, 2026

Published

on

By

BEIJING, April 27, 2026 /PRNewswire/ — Weibo Corporation (NASDAQ: WB and HKEX: 9898), a leading social media for people to create, share and discover content, will announce its unaudited financial results for the first quarter 2026 before the U.S. market opens on Thursday, May 28, 2026. Following the announcement, Weibo’s management team will host a conference call from 7 AM – 8 AM Eastern Time on May 28, 2026 (or 7 PM – 8 PM Beijing Time on May 28, 2026) to present an overview of the Company’s financial performance and business operations.

Participants who wish to dial in to the teleconference must register through the below public participant link. Dial in and instruction will be in the confirmation email upon registering.

Participants Registration Link: https://register-conf.media-server.com/register/BIb549b1f6935046d98b52a0fe61be918e

Additionally, a live and archived webcast of this conference call will be available at http://ir.weibo.com.

About Weibo Corporation

Weibo is a leading social media for people to create, share and discover content online. Weibo combines the means of public self-expression in real time with a powerful platform for social interaction, content aggregation and content distribution. Any user can create and post a feed and attach multi-media and long-form content. User relationships on Weibo may be asymmetric; any user can follow any other user and add comments to a feed while reposting. This simple, asymmetric and distributed nature of Weibo allows an original feed to become a live viral conversation stream.

Weibo enables its advertising and marketing customers to promote their brands, products and services to users. Weibo offers a wide range of advertising and marketing solutions to companies of all sizes. The Company generates a substantial majority of its revenues from the sale of advertising and marketing services, including the sale of social display advertisement and promoted marketing offerings. Designed with a “mobile first” philosophy, Weibo displays content in a simple information feed format and offers native advertisement that conform to the information feed on our platform. To support the mobile format, we have developed and continuously refining our social interest graph recommendation engine, which enables our customers to perform people marketing and target audiences based on user demographics, social relationships, interests and behaviors, to achieve greater relevance, engagement and marketing effectiveness

Contact:
Investor Relations
Weibo Corporation
Phone: +86 10 5898-3336
Email: ir@staff.weibo.com 

View original content:https://www.prnewswire.com/news-releases/weibo-corporation-to-report-first-quarter-2026-financial-results-on-may-28-2026-302754018.html

SOURCE Weibo Corporation

Continue Reading

Technology

Perceptive eClinical Launches Technology-Enabled Clinical Supply Consultancy in Alliance with Trialzen

Published

on

By

Expert-led clinical supply strategy powered by advanced planning and analytics technologies.

NOTTINGHAM, England and LASNE, Belgium, April 27, 2026 /PRNewswire/ — Perceptive eClinical, a leading provider of interactive response technology (IRT) and eClinical solutions, and Trialzen, an expert-led Forecasting and Supply Technology company, today announced an alliance supporting Perceptive eClinical in the launch of its Clinical Intelligence Consultancy Service, Perceptive Clinical Intelligence. This transforms its long–standing clinical supply expertise into a fully integrated, expert–led service spanning the entire clinical trial lifecycle and enabled by Trialzen’s advanced clinical supply planning technologies.

Perceptive Clinical Intelligence combines Perceptive’s deep expertise in randomization and clinical supply optimization with data-driven, technology enabled mathematical optimization, simulation, and forecasting to support smarter planning across the trial lifecycle. This integrated offering helps sponsors design, stress test, and manage clinical supply strategies with greater confidence and operational control. By formalizing its in-house expertise and therapeutic experience, Perceptive unifies randomization, trial supply management technologies and clinical supply consulting to enable more informed, scalable, and lower risk supply decision making.

“Clinical trial supply decisions are too critical to rely on tools alone,” said Malcolm Morrissey, Head of Perceptive Clinical Intelligence. “While supply discussions often focus on stock levels and overage, the real risk is patient impact. Supply availability determines whether visits happen, treatment is delivered on time, and sites can operate with confidence. Effective supply management means looking beyond IP numbers to understand patient continuity and visit level risk across the entire trial.”

Industry benchmarks show that approximately 50% of Clinical Finished Goods (CFG) manufactured for clinical trials are never administered to patients, representing hundreds of millions of dollars in wasted drug supply each year1.

“Setting up Perceptive Clinical Intelligence reflects the next step in Perceptive’s evolution, combining deep clinical supply and randomization expertise with data–driven technology to enable smarter supply planning, and increased supply confidence, and continuity across the trial lifecycle,” said Shaun Hopgood, Chief Operating Officer at Perceptive eClinical.

Perceptive eClinical and Trialzen have each delivered proven results for sponsors, with real–world engagements generating savings exceeding $1 million and materially reducing supply overage.

A Technology Enabled, Expert-Led Approach

Delivered by Perceptive’s in–house specialists, the consultancy is built on 30 years of experience supporting biotech and large pharma across randomization and clinical supply management. It combines Perceptive’s proven supply–modelling expertise with Trialzen’s advanced calculation and simulation engine, fully integrated into Perceptive’s next–generation platform, Clinphone Pro.

Anchored in deep oncology expertise, where global scale, complex dosing, and multi–layered supply chains increase planning risk, the consultancy also draws on experience across Endocrinology and Metabolism, and Infectious Diseases, and supports emerging areas such as Precision and Nuclear Medicine, and Cell and Gene Therapies. 

Reflecting on this alliance and its objectives, Cedric Druck, CEO and Co–Founder of Trialzen, commented: “Trialzen was built by clinical supply experts who spent years watching planning decisions get made on spreadsheets and gut feel, then handed off to execution systems with no feedback loop. This collaboration with Perceptive closes that gap. By integrating our forecasting and simulation capabilities directly with their IRT platform, we enable sponsors to move from scenario planning to operational action in a single environment, with full transparency at every step.”

At the heart of this alliance is a shared belief that clinical supply planning and execution should live in one connected environment. “Together, Perceptive and Trialzen are working toward a unified way of operating, where strategic decisions and day–to–day execution come together, enabling greater visibility, smarter scenarios, and more confident supply decisions from manufacturing through to patient dosing”. said Tony Street, Senior Vice President Strategy at Trialzen.

Clients benefit from:

Faster study start-up and smoother amendments through early supply optimizationHigher quality supply decisions driven by expert oversight and data backed insightGreater confidence through strategic expert consultancy for complex trialsMid-study forecast adjustments and up-to-date quantitative support for key decisions

About Perceptive eClinical

Perceptive eClinical is a trusted leader in delivering advanced trial capabilities. With over 30 years of proven Interactive Response Technology (IRT) and supply management expertise, more than 500 regulatory approvals and support for three million patients worldwide, we deliver reliability, security and precision. This is reflected in our consistently high customer satisfaction score of 4.5 out of 5 over the past three years. Our future-proof IRT solution, Clinphone Pro, helps sponsors manage the speed, complexity and personalization of modern clinical trials. Built for flexibility and seamless integration, it supports smarter, more efficient studies across all phases and therapeutic areas. In 2025, Perceptive eClinical was recognized as a leader in Everest Group’s PEAK Matrix® Assessment for RTSM Solutions, affirming our commitment to innovation, global delivery excellence and measurable value for sponsors and CROs.

About Trialzen

Trialzen is a technology company built by industry experts specializing in clinical trial supply forecasting and planning. Its Forecast & Planning Solution (FPS) is a purpose-built SaaS platform that enables sponsors and CROs to model, simulate, and optimize clinical supply strategies across the full trial lifecycle. Built by clinical supply experts, Trialzen combines advanced mathematical modelling and analytics with a transparent, user-friendly interface, allowing teams to evaluate scenarios, anticipate risk, and make informed supply decisions with speed and confidence. 

Sources

McKinsey & Company, Clinical Supply Chains insights

Media Contact: Zara Broadfield, Marketing Director Perceptive eClinical, zara.broadfield@perceptive.com 

Logo – https://mma.prnewswire.com/media/2965426/Perceptive_eClinical.jpg
Logo – https://mma.prnewswire.com/media/2965427/5936695/Trialzen.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/perceptive-eclinical-launches-technologyenabled-clinical-supply-consultancy-in-alliance-with-trialzen-302754074.html

Continue Reading

Technology

Mouser Electronics New Product Insider: Over 9,000 New Parts Added in First Quarter of 2026

Published

on

By

SHANGHAI, April 27, 2026 /PRNewswire/ — As an authorized distributor, Mouser Electronics, Inc. is focused on the rapid introduction of new products and technologies, giving customers an edge and helping speed time to market. Over 1,200 semiconductor and electronic component manufacturer brands count on Mouser to help them introduce their products into the global marketplace. Mouser’s customers can expect 100% certified, genuine products that are fully traceable from each manufacturer.

Last quarter, Mouser launched more than 9,000 part numbers ready for shipment. Some of the products introduced by Mouser from January through March 2026 include:

STMicroelectronics STM32C5 Arm® Cortex®-M33 Microcontrollers
The STM32C5 microcontrollers (MCUs) from STMicroelectronics are specifically designed to boost the performance of billions of tiny smart devices across factories, homes, cities, and infrastructure while meeting stringent cost, size, and power constraints. Based on ST’s proprietary 40 nm manufacturing process, the STM32C5 MCUs can run tasks noticeably faster than many entry-level chips currently in use. This gives products more room to include features such as improved sensing, smoother control, and enhanced user experiences while keeping dynamic power consumption low. The MCUs also integrate security features that help safeguard products against tampering and cyber risks.EDATEC ED-CM0NANO Single-Board Computer
The ED-CM0NANO is a single-board computer (SBC) from EDATEC, based on the Raspberry Pi Compute Module Zero (CM0). The ED-CM0NANO features a quad-core Arm Cortex-A53 processor running at up to 1 GHz, a Broadcom VideoCore-IV graphics processor, and a wide range of connectivity options. Optional Wi-Fi® support with an external antenna enables wireless connectivity, while integrated real-time clock (RTC) and watchdog timer enhance system reliability. These features make the ED-CM0NANO ideal for industrial control systems and Internet of Things (IoT) applications.Sensata Technologies MGD Resonix™ Refrigerant Leak Sensor
The MGD Resonix™ sensor from Sensata delivers high accuracy and fast response times in a compact module that fits into the smallest heating, ventilation, air conditioning (HVAC), and refrigeration equipment. The MGD series offers superior resistance to overexposure and poisoning, as well as to high temperatures (working temperatures up to 105 °C) and humidity. These devices also have a service life of more than 15 years with no need for calibration, making them the ideal leak-detection component for A2L HVAC and refrigeration systems.u-blox ANN-MB3 Triple-Band GNSS Antenna
The ANN-MB3 from u-blox is a best-in-class L1/L2/L5 triple-band RTK real-time kinematic (RTK) solution ideal for the F20 high-precision GNSS. Optimized for seamless integration, the ANN-MB3 antenna delivers exceptional performance with a robust design. The antenna’s compact (62 × 80 × 25.5 mm) form factor and flexible installation options enable the adoption of high-precision positioning technologies across industrial, automotive, and robotics applications.

To see more of the New Product Insider highlights, go to https://info.mouser.com/new_products/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/mouser-electronics-new-product-insider-over-9-000-new-parts-added-in-first-quarter-of-2026–302754079.html

SOURCE Mouser Electronics

Continue Reading

Trending